| Stereochemistry | ABSOLUTE |
| Molecular Formula | C28H38N2O5 |
| Molecular Weight | 482.6117 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(CCN2CCC[C@H](CN3CCC4=CC(OC)=C(OC)C=C4CC3=O)C2)C=C1OC
InChI
InChIKey=OBUFMJDDZTXJPY-NRFANRHFSA-N
InChI=1S/C28H38N2O5/c1-32-24-8-7-20(14-25(24)33-2)9-12-29-11-5-6-21(18-29)19-30-13-10-22-15-26(34-3)27(35-4)16-23(22)17-28(30)31/h7-8,14-16,21H,5-6,9-13,17-19H2,1-4H3/t21-/m0/s1
| Molecular Formula | C28H38N2O5 |
| Molecular Weight | 482.6117 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Cilobradine is an Hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker patented by a pharmaceutical company Boehringer Ingelheim G.m.b.H. for sinus tachycardia treatment. In clinical trials Cilobradine decrease Heart rate. Chronically increased heart rate (HR) is a risk factor for mortality and morbidity with adverse consequences on vascular function, atherogenesis, myocardial ischemia, myocardial energetics and left the ventricular function. Heart rate response was found to be concentration-dependent and appeared with a significant delay with respect to the time course of cilobradine in plasma.
